Abstract
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, 68Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of 18F-labeled agents. Among others, [18F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [18F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this 18F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [18F]DCFPyL in various clinical settings for men with PC.
Highlights
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC)
Prostate-specific membrane antigen (PSMA)-targeted molecular imaging has seen an unprecedented success in recent years for staging, restaging, and response assessment in men with prostate cancer (PC) [1]
In this review we provide an overview of the current clinical utility of [18F]DCFPyL PET/computed tomography (CT) in men with PC
Summary
Prostate-specific membrane antigen (PSMA)-targeted molecular imaging has seen an unprecedented success in recent years for staging, restaging, and response assessment in men with prostate cancer (PC) [1]. The authors concluded that with [18F]DCFPyL, improved sensitivity for relapse detection after prostatectomy can be achieved, even for only moderately increased PSA levels [41] Based on those encouraging findings, multiple recent prospective trials further provided evidence on high detection efficiency in patients with BCR. Independent of staging or restaging, a recent meta-analysis including 426 patients reported on a pooled detection rate of 89 % for PSA ≥ 0.5 ng/mL and 49 % for PSA to early progression [49], supporting the notion that [18F]DCFPyL can be used to identify high-risk individuals even under such therapies In another prospective Phase II trial enrolling patients with newly diagnosed PC, patients underwent a baseline [18F]DCFPyL pelvic PET/MRI followed by 3 cycles of neoadjuvant docetaxel and androgen deprivation therapy. Such studies have been conducted using 68Ga-PSMA agents and remain to be carried out with [18F]DCFPyL PET/CT
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
